Passage Bio, Inc. (PASG)
4.75
+0.14
(+3.04%)
USD |
NASDAQ |
Sep 03, 16:00
4.63
-0.12
(-2.53%)
After-Hours: 07:29
Passage Bio Research and Development Expense (TTM) : 17.16M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.16M |
| March 31, 2026 | 19.63M |
| December 31, 2025 | 23.28M |
| September 30, 2025 | 27.42M |
| June 30, 2025 | 31.76M |
| March 31, 2025 | 36.38M |
| December 31, 2024 | 40.18M |
| September 30, 2024 | 42.78M |
| June 30, 2024 | 47.82M |
| March 31, 2024 | 54.72M |
| December 31, 2023 | 60.02M |
| September 30, 2023 | 65.52M |
| June 30, 2023 | 67.18M |
| March 31, 2023 | 76.68M |
| Date | Value |
|---|---|
| December 31, 2022 | 86.05M |
| September 30, 2022 | 101.36M |
| June 30, 2022 | 112.62M |
| March 31, 2022 | 118.92M |
| December 31, 2021 | 117.67M |
| September 30, 2021 | 112.64M |
| June 30, 2021 | 106.85M |
| March 31, 2021 | 93.64M |
| December 31, 2020 | 81.79M |
| September 30, 2020 | 63.83M |
| June 30, 2020 | 53.42M |
| March 31, 2020 | 39.82M |
| December 31, 2019 | 29.74M |
| September 30, 2019 | 25.71M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ARS Pharmaceuticals, Inc. | 15.23M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |